Medical oncologists outline localized therapy options for patients with early- and intermediate-stage hepatocellular carcinoma.
Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST
Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC
CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
Rintatolimod/Durvalumab Dose Appears Tolerable in Pancreatic Cancer
Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer
Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.